A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor

Summary

Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with advanced or metastatic gastrointestinal stromal tumor who failed from imatinib therapy.

Timeline

Start

2012-03

Primary completion

2018-12

Completion

2019-06

Drugs

Indications